Luzhu Biotechnology's LZ901 Herpes Zoster Vaccine Advances Through Clinical Development with Strong Safety Profile
核心洞察
Luzhu Biotechnology (搜索)'s recombinant herpes zoster (搜索) vaccine LZ901 successfully completed Phase II clinical trials in China with 450 subjects aged 50-70, demonstrating superior immunogenicity compared to placebo groups.
The vaccine showed a favorable safety profile with adverse events primarily occurring within 0-7 days and no Grade IV adverse events or serious adverse events observed during the Phase II trial.
LZ901 completed Phase I clinical trials in the United States in September 2025, with both high-dose and low-dose groups showing good safety and immunogenicity compared to placebo.
Beijing Luzhu Biotechnology Co., Ltd. has achieved significant clinical milestones for its investigational recombinant herpes zoster (搜索) vaccine LZ901, successfully completing Phase II trials in China and Phase I trials in the United States. The vaccine, designed to prevent shingles (搜索) and related complications including postherpetic neuralgia (搜索) in adults aged 40 and above, represents a promising addition to the herpes zoster prevention landscape.
Phase II Clinical Trial Results Demonstrate Strong Efficacy
The Phase II clinical trial in China, completed in May 2023, enrolled 450 healthy subjects aged 50-70 years in a randomized, double-blinded, placebo-controlled study design. The trial's primary objectives focused on evaluating immunogenicity and safety across different dosage levels, while secondary objectives assessed immune persistence.
Results showed that the high-dose LZ901 group achieved significantly higher geometric mean concentration (GMC), geometric mean titer (GMT), and positive conversion rates of antibody compared to low-dose cohorts. Both high-dose and low-dose LZ901 groups demonstrated significantly superior immunogenicity metrics compared to the placebo group.
Favorable Safety Profile Supports Clinical Advancement
Safety data from the Phase II trial revealed a well-tolerated profile, with adverse events primarily occurring within the first seven days post-vaccination. The incidence rates for Grade I, Grade II, and Grade III adverse events were approximately 23.74%, 6.02%, and 1.00%, respectively. Notably, no Grade IV adverse events or serious adverse events were observed throughout the trial period.
The safety findings were reinforced by the completed Phase I clinical trial in the United States, which began in February 2023 and concluded in September 2025. This randomized, double-blind, placebo-controlled, dose-escalation study enrolled 66 healthy subjects aged 50-70 years. Only the low-dose group showed mild vaccine-related adverse reactions at 4.35%, while neither the high-dose group nor the placebo group exhibited any vaccine-related adverse reactions.
Regulatory Progress and Market Positioning
Based on Phase II clinical trial data, Luzhu Biotechnology (搜索) has determined the Phase III dosage at 100 μg/0.5mL/vial, administered as a two-dose regimen with the second dose given 30 days after the first. The company is advancing multi-center, randomized, double-blinded, placebo-controlled Phase III clinical trials in China.
The Biologics License Application for LZ901 has been accepted by China's National Medical Products Administration (搜索) and is currently under review. LZ901 holds the distinction of being the only domestic vaccine in China conducting clinical trials in both the United States and China, having received IND approval from the FDA in July 2022.
Competitive Advantages in Growing Market
LZ901 is positioned as a recombinant protein vaccine that induces cellular immune responses while avoiding risks associated with live attenuated virus vaccines. The vaccine's liquid formulation contains only aluminum hydroxide adjuvant and is free of immune stimulants, contributing to its favorable safety profile.
The company anticipates competitive retail pricing for LZ901, requiring only two injections per treatment without a third booster shot, potentially offering cost advantages compared to other commercially available herpes zoster (搜索) vaccines in China. This pricing strategy addresses the growing market demand driven by China's aging population, with the National Health Commission (搜索) recommending herpes zoster vaccination for people aged 50 years and older.
The vaccine's high stability formulation offers advantages in storage and transportation, while its ease of use provides additional competitive benefits in the marketplace. These factors, combined with clinical trial data comparable to imported alternatives, position LZ901 with strong market potential as it advances through regulatory review.